

# K252533 HemoSphere Alta Advanced Monitoring Platform (ALTAALL1)

Dec 18, 2025  
128 days to decision

K252533 · Product code: **DQK** · Cardiovascular  
Source: <https://www.510kdatabase.net/k252533/>

## SUBMISSION DETAILS

---

|                       |  |
|-----------------------|--|
| Decision              | Substantially Equivalent (Cleared)       |
| Submission type       | Traditional                              |
| Device classification | Computer, Diagnostic, Programmable (DQK) |
| Date received         | Aug 12, 2025                             |
| Decision date         | Dec 18, 2025                             |
| Days to decision      | 128 days                                 |
| Third-party review    | No                                       |
| Combination product   | No                                       |
| PCCP authorized       | No                                       |
| Summary / Statement   | Summary                                  |
| Other names           | ALTACR1; ALTASR1)                        |

## APPLICANT

---

|                |   |
|----------------|---|
| Company        | <b>Edwards Lifesciences</b>                                 |
| Location       | Irvine, CA, US  |
| Contact        | Niharika Mirji  |
| Website        | <a href="http://www.edwards.com">http://www.edwards.com</a> |
| 510(k) history | 20 submissions · 19 cleared · 2011-2026                     |

Edwards Lifesciences is the leading global structural heart innovation company dedicated to improving patient lives through breakthrough cardiovascular technologies. The company partners with physicians to develop products for patients fighting heart disease, with a manufacturing facility in Irvine, US. Edwards Lifesciences has received FDA 510(k) clearances from total submissions since 2011. The company specializes in Cardiovascular devices, which represent the dominant focus of its regulatory portfolio. The latest clearance in 2025 reflects continued innovation and acti...